Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection
Florian van Bömmel, Thomas Wünsche, Stefan Mauss, Petra Reinke, Alexandra Bergk, Dirk Schürmann, Bertram Wiedenmann, Thomas Berg – 24 November 2004 – Adefovir dipivoxil was recently approved for the treatment of wild‐type and lamivudine‐resistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender of adefovir that is used in the treatment of HIV infected patients, has recently been shown to also be effective in patients with lamivudine‐resistant HBV infection.